Ventrus’ anal fissure drug fails in trial, shares slump

(Reuters) – Ventrus Biosciences Inc said its lead experimental drug to treat anal fissures failed to reduce pain more than a placebo in a late-stage trial, sending its shares plunging 67 percent in…


Leave a Reply

Your email address will not be published.